Impaired smooth-pursuit in Parkinson's disease: normal cue-information memory, but dysfunction of extra-retinal mechanisms for pursuit preparation and execution

Eye movements in Parkinson's disease: from neurophysiological mechanisms to diagnostic tools

Movement disorders such as Parkinson's disease (PD) impact oculomotor function - the ability to move the eyes accurately and purposefully to serve a multitude of sensory, cognitive, and secondary motor tasks. Decades of neurophysiological research in monkeys and behavioral studies in humans have characterized the neural basis of healthy oculomotor control. This review links eye movement abnormalities in persons living with PD to the underlying neurophysiological mechanisms and pathways. Building on this foundation, we highlight recent progress in using eye movements to gauge symptom severity, assess treatment effects, and serve as potential precision biomarkers. We conclude that whereas eye movements provide insights into PD mechanisms, based on current evidence they appear to lack sufficient sensitivity and specificity to serve as a standalone diagnostic tool. Their full potential may be realized when combined with other disease indicators in big datasets.

Istradefylline Improves Impaired Smooth Pursuit Eye Movements in Parkinson's Disease

INTRODUCTION

Patients with Parkinson's disease (PD) exhibit alterations in eye movement control, primarily diverse oculomotor deficits which include hypometric saccade and impaired smooth pursuit with reduced pursuit-gain necessitating catch-up saccades. The effects of dopaminergic treatment of PD on eye movements are controversial. Previous studies suggest that smooth pursuit eye movements (SPEMs) are not directly influenced by the dopaminergic system. The nondopaminergic drug istradefylline, a selective adenosine A2A receptor antagonist, reduces the OFF time and improves somatomotor function in levodopa-treated PD. Here, we investigated whether istradefylline improves SPEMs in PD, and determined whether oculomotor performance is associated with somatomotor performance.

METHODS

Using an infrared video eye tracking system, we quantified horizontal SPEMs in six patients with PD before and 4-8 weeks after initiation of istradefylline administration. A further five patients with PD were tested before and after a 4-week interval without istradefylline to control for practice effects. We evaluated smooth pursuit gain (eye velocity/target velocity), accuracy of smooth pursuit velocity, and saccade rate during pursuit before and after istradefylline administration during the ON state.

RESULTS

Patients received istradefylline by single daily oral administration at 20 to 40 mg. Eye tracking data were obtained 4-8 weeks after initiation of istradefylline administration. Istradefylline increased smooth pursuit gain and the accuracy of smooth pursuit velocity, and tended to decrease saccade rates during pursuit.

CONCLUSIONS

Istradefylline ameliorated the oculomotor deficit in SPEM of patients with PD, although differences in somatomotor performance before and after istradefylline treatment were not significant during ON periods. The discrepancy observed between the oculomotor and somatomotor responses to istradefylline supports previous findings that SPEM is at least partially under nondopaminergic control.

Impaired Ocular Tracking and Cortical Atrophy in Idiopathic Rapid Eye Movement Sleep Behavior Disorder

BACKGROUND

Idiopathic rapid eye movement sleep behavior disorder (iRBD) is a prodromal stage of synucleinopathies. Patients with synucleinopathies frequently display eye movement abnormalities. However, whether patients with iRBD have eye movement abnormalities remains unknown.

OBJECTIVE

The aim of this study was to assess eye movement abnormalities and related gray matter alterations and explore whether such abnormalities can serve as biomarkers to indicate phenoconversion to synucleinopathies in iRBD.

METHODS

Forty patients with iRBD with early disease progression and 35 healthy control subjects participated in a 15-minute ocular-tracking task that evaluated their control of eye movement abilities. They also underwent clinical assessments for olfactory function, nonmotor symptoms, and autonomic symptoms, all of which are biomarkers to predict phenoconversion to synucleinopathies in iRBD. A subgroup of the participants (20 patients with iRBD and 20 healthy control subjects) also participated in structural magnetic resonance imaging.

RESULTS

The ocular-tracking ability in patients with iRBD was inferior to that of healthy control subjects in two aspects: pursuit initiation and steady-state tracking. Cortical thinning in the right visual area V4 in patients with iRBD is coupled with impaired pursuit initiation. Furthermore, prolonged pursuit initiation in patients with iRBD exhibits a trend of correlation with olfactory loss, the earliest biomarker that develops prior to other prodromal biomarkers.

CONCLUSIONS

We found ocular-tracking abnormalities in patients with iRBD even early in their disease progression that have not been reported before. These abnormalities are coupled with atrophy of brain areas involved in the perception of object motion and might indicate phenoconversion to synucleinopathies in iRBD. © 2022 International Parkinson and Movement Disorder Society.

Abnormalities of smooth pursuit in Parkinson's disease: A systematic review

•

Abnormalities of saccades, vergence and smooth pursuit have been found in PD.

•

SPEM abnormalities in PD consist of reduced gain and saccadic pursuit.

•

PD patients have normal SPEM interspersed with catch up and anticipatory saccades.

•

SP may reflect an inability to inhibit extraneous saccades or be a sign of executive dysfunction.

•

Degeneration of SNr in PD may be reason behind SPEM abnormalities in PD.

Smooth pursuit eye movement (SPEM) abnormalities are commonly seen in Parkinson’s disease (PD). Both reduced speed and saccades seen during SPEM, also known as saccadic pursuit (SP), have been studied in PD. A comprehensive literature review analyzed 26 studies of SPEM and PD. It appears that a greater proportion of PD patients have SPEM abnormalities consisting of reduced SPEM gain and/or SP compared to the normal population. It is not clear whether SPEM abnormalities are present early in the disease or begin sometime during disease progression. SPEM abnormalities may be correlated with disease severity but do not fluctuate or respond to dopaminergic medication in the same manner as other motor symptoms in PD. SPEM in PD is composed of normal SPEM interspersed with SP composed of both catch up and anticipatory saccades. This differs from other neurodegenerative disorders and may be related to an inability to inhibit extraneous saccades or to increased distraction reflecting executive dysfunction. Because the basal ganglia are involved in SPEM physiology, degeneration of the SNr neurons in PD may explain abnormal SPEM in this disorder. Since dementia, aging and medication effects influence SPEM, they should be controlled for in future studies of SPEM in PD. SP is easily detected on clinical exam and may be a biomarker for the disease or for disease progression. Oculomotor testing can be an important part of the Parkinson’s exam.

Neuropsychiatric aspects of Parkinson disease psychopharmacology: Insights from circuit dynamics

Parkinson disease (PD) is a neurodegenerative disorder with a complex pathophysiology characterized by the progressive loss of dopaminergic neurons within the substantia nigra. Persons with PD experience several motoric and neuropsychiatric symptoms. Neuropsychiatric features of PD include depression, anxiety, psychosis, impulse control disorders, and apathy. In this chapter, we will utilize the National Institutes of Mental Health Research Domain Criteria (RDoC) to frame and integrate observations from two prevailing disease constructions: neurotransmitter anomalies and circuit physiology. When there is available evidence, we posit how unified translational observations may have clinical relevance and postulate importance outside of PD. Finally, we review the limited evidence available for pharmacologic management of these symptoms.

Eye tracking - The overlooked method to measure cognition in neurodegeneration?

Eye tracking (ET) studies are becoming increasingly popular due to rapid methodological and technological advances as well as the development of cost efficient and portable eye trackers. Although historically ET has been mostly employed in psychophysics or developmental cognition studies, there is also promising scope to use ET for movement disorders and measuring cognitive processes in neurodegeneration. Particularly, ET can be a powerful tool for cognitive and neuropsychological assessments of patients with pathologies affecting motor and verbal abilities, as tasks can be adapted without requiring motor (except eye movements) or verbal responses. In this review, we will examine the existing evidence of ET methods in neurodegenerative conditions and its potential clinical impact for cognitive assessment. We highlight that current evidence for ET is mostly focused on diagnostics of cognitive impairments in neurodegenerative disorders, where it is debatable whether it has any more sensitivity or specificity than existing cognitive assessments. By contrast, there is currently a lack of ET studies in more advanced disease stages, when patients' motor and verbal functions can be significantly affected, and standard cognitive assessments are challenging or often not possible. We conclude that ET is a promising method not only for cognitive diagnostics but more importantly, for potential cognitive disease tracking in progressive neurodegenerative conditions.

Voluntary Saccade Training Protocol in Persons With Parkinson's Disease and Healthy Adults

Background: Voluntary saccade function gradually decreases during both the progression of Parkinson's disease (PD) and neurologically healthy adult aging. Voluntary saccades display decreased length and increased saccade latency, duration, and the number of compensatory saccades in aging and PD. Saccades serve as the key eye movement for maintaining salient features of the visual environment on the high visual acuity fovea of the retina. Abnormal saccade behavior has been associated with freezing of gait in PD. We have not identified any studies that have investigated improvement in voluntary saccade function using voluntary saccade training. Objective: We report an experimental protocol that tests a training paradigm following the principle of specificity to improve voluntary saccade velocity and amplitude, while decreasing latency and the number of compensatory saccades. Methods: Persons with PD (n = 22) and persons with no known neurological disorders (n = 22) between the ages of 40 and 65 years will be recruited. In a randomized-block study design, all participants will perform voluntary saccades to targets in eight cardinal and intercardinal directions. In each of the eight sessions during the four-week intervention period, participants will train at three target amplitudes. Participants will perform 40 trials for each amplitude block, consisting of five randomly presented repetitions for each direction. Voluntary and reflexive saccades will be recorded pre- and post-intervention, along with clinical mobility assessment using the Movement Disorder Society Unified Parkinson's Disease Rating Scale. Mobility scores, the amplitude, latency, and duration of the first saccade, and the number of saccades to reach the fixation target will be analyzed using an ANOVA of mixed effects. Discussion: This protocol holds promise as a potential method to improve voluntary saccade function in persons with PD. Should persons with PD not improve on any outcome following the intervention, this lack of response may support the use of saccade assessment as a response biomarker for the diagnosis of PD. Trial Registration: This protocol was retrospectively registered at ISRCTN (ISRCTN.com) since July 25, 2018. The first participant was recruited March 12, 2016. The protocol identifier is 17784042. Descriptive Title: A two-arm, pre/post-protocol to compare the effects of a four-week voluntary saccade training intervention in persons with Parkinson's disease and healthy adults aged forty years or older.

Application of eye tracking in medicine: A survey, research issues and challenges

The performance and quality of medical procedures and treatments are inextricably linked to technological development. The application of more advanced techniques provides the opportunity to gain wider knowledge and deeper understanding of the human body and mind functioning. The eye tracking methods used to register eye movement to find the direction and targets of a person's gaze are well in line with the nature of the topic. By providing methods for capturing and processing images of the eye it has become possible not only to reveal abnormalities in eye functioning but also to conduct cognitive studies focused on learning about peoples' emotions and intentions. The usefulness of the application of eye tracking technology in medicine was proved in many research studies. The aim of this paper is to give an insight into those studies and the way they utilize eye imaging in medical applications. These studies were differentiated taking their purpose and experimental paradigms into account. Additionally, methods for eye movement visualization and metrics for its quantifying were presented. Apart from presenting the state of the art, the aim of the paper was also to point out possible applications of eye tracking in medicine that have not been exhaustively investigated yet, and are going to be a perspective long-term direction of research.

Clinical application of eye movement tasks as an aid to understanding Parkinson's disease pathophysiology

Parkinson's disease (PD) is a progressive neurodegenerative disorder of the basal ganglia. Most PD patients suffer from somatomotor and oculomotor disorders. The oculomotor system facilitates obtaining accurate information from the visual world. If a target moves slowly in the fronto-parallel plane, tracking eye movements occur that consist primarily of smooth-pursuit interspersed with corrective saccades. Efficient smooth-pursuit requires appropriate target selection and predictive compensation for inherent processing delays. Although pursuit impairment, e.g. as latency prolongation or low gain (eye velocity/target velocity), is well known in PD, normal aging alone results in such changes. In this article, we first briefly review some basic features of smooth-pursuit, then review recent results showing the specific nature of impaired pursuit in PD using a cue-dependent memory-based smooth-pursuit task. This task was initially used for monkeys to separate two major components of prediction (image-motion direction memory and movement preparation), and neural correlates were examined in major pursuit pathways. Most PD patients possessed normal cue-information memory but extra-retinal mechanisms for pursuit preparation and execution were dysfunctional. A minority of PD patients had abnormal cue-information memory or difficulty in understanding the task. Some PD patients with normal cue-information memory changed strategy to initiate smooth tracking. Strategy changes were also observed to compensate for impaired pursuit during whole body rotation while the target moved with the head. We discuss PD pathophysiology by comparing eye movement task results with neuropsychological and motor symptom evaluations of individual patients and further with monkey results, and suggest possible neural circuits for these functions/dysfunctions.

Frontal cortical dysfunction in Parkinson's disease (PD): Comparison of memory-based smooth-pursuit and anti-saccade tasks, and neuropsychological and motor symptom evaluations

We reported recently that during a memory-based smooth-pursuit task, most Parkinson's disease (PD) patients exhibited normal cue-information memory but impaired smooth-pursuit preparation and execution. A minority of PD patients had abnormal cue-information memory or difficulty in understanding the task. To further examine differences between these two groups, we assigned an anti-saccade task and compared correct rates with various neuropsychological and motor symptom evaluations. The anti-saccade task requires voluntary saccades in the opposite direction to a visual stimulus, and patients with frontal cortical impairments are known to exhibit reflexive saccades (errors). We classified PD patients into 2 groups: one with normal cue-information memory during memory-based smooth-pursuit (n = 14), and the other with abnormal cue-information memory or with difficulty in understanding the memory task (n = 6). The two groups had significantly different anti-saccade correct rates and frontal assessment battery (FAB) scores (P < 0.01). Anti-saccade correct rates of individual patients (n = 20) correlated significantly with FAB scores (P < 0.01) but not with age, Hoehn-Yahr stage, unified PD rating scale (UPDRS) part III or mini-mental state examination (MMSE) scores. Among FAB subtests, significant correlation was obtained only with motor programming scores. These results suggest that performance of memory-based smooth-pursuit and/or anti-saccades depend on frontal cortical function or dysfunction.

[Visual tracking with/without passive whole-body rotation in Parkinson's disease (PD): Dissociation of smooth-pursuit and cancellation of vestibulo-ocular reflex (VOR)]

Although impaired smooth-pursuit in Parkinson's disease (PD) is well known, reports are conflicting on the ability to cancel vestibulo-ocular reflex (VOR) when the target moves with head, requiring gaze-pursuit. To compare visual tracking performance with or without passive whole-body rotation, we examined eye movements of 10 PD patients and 6 age-matched controls during sinusoidal horizontal smooth-pursuit and passive whole-body rotation (0.3 Hz, ± 10°). Three tasks were tested: smooth-pursuit, VOR cancellation, and VORx1 while subjects fixated an earth-stationary spot during whole-body rotation. Mean ± SD eye velocity gains (eye velocities/stimulus velocities) of PD patients during the 3 tasks were 0.32 ± 0.24 0.25 ± 0.22, 0.85 ± 0.20, whereas those of controls were 0.91 ± 0.06, 0.14 ± 0.07, 0.94 ± 0.05, respectively. Difference was significant between the two subject groups only during smooth-pursuit. Plotting eye-velocity gains of individual subjects during VOR cancellation against those during smooth-pursuit revealed significant negative linear correlation between the two parameters in the controls, but no correlation was found in PD patients. Based on the regression equation of the controls, we estimated expected eye velocity gains of individual subjects during VOR cancellation from their smooth-pursuit gains. Estimated gains of PD patients during VOR cancellation were significantly different from their actual gains, suggesting that different neural mechanisms operate during VOR cancellation in the controls and PD.